Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigates peripheral blood lymphocytes engineered with a murine T-cell receptor targeting the G12V mutation in RAS for patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• G12V RAS TCR-T cell therapy (T-cell receptor-engineered T cells targeting G12V-mutated RAS in HLA-A*11:01)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Cancer, Gastric Cancer | Phase 1, Phase 2 | Status: RECRUITING